Discovery and development of anti-HBV agents and their resistance

Molecules

Volumn 15, Issue 9, 2010, Pages 5878-5908

  Kim, Kyun Hwan ^a   Kim, Nam Doo ^b   Seong, Baik Lin ^c  

^a Konkuk University   (South Korea)

^b Equispharm Co Ltd   (South Korea)

^c Yonsei University   (South Korea)

Author keywords

Antiviral agent; Drug development; Drug resistance; Hepatitis B virus; Modeling; Rational drug design

Indexed keywords

ANTIVIRUS AGENT;

DRUG DEVELOPMENT; DRUG EFFECT; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; METHODOLOGY; REVIEW;

ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS;

EID: 77957311078     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15095878     Document Type: Review

References (133)

1. Tiollais, P.; Charnay, P.; Vyas, G. N. Biology of hepatitis B virus. Science 1981, 213, 406-411.
2. Robinson, W. S. Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu. Rev. Med. 1994, 45, 297-323.
3. Kremsdorf, D.; Soussan, P.; Paterlini-Brechot, P.; Brechot, C. Hepatitis B virus-related hepatocellular carcinoma: Paradigms for viral-related human carcinogenesis. Oncogene 2006, 25, 3823-3833.
4. Brechot, C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms. Gastroenterology 2004, 127, S56-S61.
5. Seeger, C.; Zoulim, F.; Mason, W. S. Hepadnaviruses. In Fields Virology, 5th ed.; Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., Straus, S. E., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007; Volume 2, pp. 2977-3029.
6. Ganem, D.; Schneider, R. J. The molecular biology of the hepatitis B viruses. In Fields Virology, 4th ed.; Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., Straus, S. E., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2001; Volume 2, pp. 2923-2970.
7. Wang, G. H.; Seeger, C. Novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 1993, 67, 6507-6512.
8. Wang, G. H.; Seeger, C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 1992, 71, 663-670.
9. Kwon, S. Y.; Park, Y. K.; Ahn, S. H.; Cho, E. S.; Choe, W. H.; Lee, C. H.; Kim, B. K.; Ko, S. Y.; Choi, H. S.; Park, E. S.; Shin, G. C.; Kim, K. H. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J. Virol. 2010, 84, 4494-4503.
10. De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 2002, 1, 13-25.
11. Mazzucco, C. E.; Hamatake, R. K.; Colonno, R. J.; Tenney, D. J. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob. Agents Chemother. 2008, 52, 598-605.
12. Innaimo, S. F.; Seifer, M.; Bisacchi, G. S.; Standring, D. N.; Zahler, R.; Colonno, R. J. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother. 1997, 41, 1444-1448.
13. Levine, S.; Hernandez, D.; Yamanaka, G.; Zhang, S.; Rose, R.; Weinheimer, S.; Colonno, R. J. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 2002, 46, 2525-2532.
14. Chang, T. T. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006, 354, 1001-1010.
15. Lai, C. L.; Shouval, D.; Lok, A. S.; Chang, T. T.; Cheinquer, H.; Goodman, Z.; De Hertogh, D.; Wilber, R.; Zink, R. C.; Cross, A.; Colonno, R.; Fernandes, L.; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006, 354, 1011-1020. (Pubitemid 43357805)
16. Sherman, M.; Yurdaydin, C.; Sollano, J.; Silva, M.; Liaw, Y. F.; Cianciara, J.; Boron-Kaczmarska, A.; Martin, P.; Goodman, Z.; Colonno, R.; Cross, A.; Denisky, G.; Kreter, B.; Hindes, R.; AI463026 BEHoLD Study Group. Entecavir for the treatment of lamivudine-refractory, HBeAgpositive chronic hepatitis B. Gastroenterology 2006, 130, 2039-2049. (Pubitemid 43816960)
17. Sherman, M.; Yurdaydin, C.; Simsek, H.; Silva, M.; Liaw, Y. F.; Rustgi, V. K.; Sette, H.; Tsai, N.; Tenney, D. J.; Vaughan, J.; Kreter, B.; Hindes, R.; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008, 48, 99-108.
18. Bryant, M. L.; Bridges, E. G.; Placidi, L.; Faraj, A.; Loi, A. G.; Pierra, C.; Dukhan, D.; Gosselin, G.; Imbach, J. L.; Hernandez, B.; Juodawlkis, A.; Tennant, B.; Korba, B.; Cote, P.; Marion, P.; Cretton-Scott, E.; Schinazi, R. F.; Sommadossi, J. P. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 2001, 45, 229-235. (Pubitemid 32039120)
19. Liaw, Y. F.; Gane, E.; Leung, N.; Zeuzem, S.; Wang, Y.; Lai, C. L.; Heathcote, E. J.; Manns, M.; Bzowej, N.; Niu, J.; Han, S. H.; Hwang, S. G.; Cakaloglu, Y.; Tong, M. J.; Papatheodoridis, G.; Chen, Y.; Brown, N. A.; Albanis, E.; Galil, K.; Naoumov, N. V. GLOBE Study Group. 2-Year GLOBE trial results: Telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136, 486-495.
20. Lai, C. L.; Gane, E.; Liaw, Y. F.; Hsu, C. W.; Thongsawat, S.; Wang, Y.; Chen, Y.; Heathcote, E. J.; Rasenack, J.; Bzowej, N.; Naoumov, N. V.; Di Bisceglie, A. M.; Zeuzem, S.; Moon, Y. M.; Goodman, Z.; Chao, G.; Constance, B. F.; Brown, N. A.; Globe Study Group. Telbivudine versu lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357, 2576-2588.
21. Lai, C. L.; Leung, N.; Teo, E. K.; Tong, M.; Wong, F.; Hann, H. W.; Han, S.; Poynard, T.; Myers, M.; Chao, G.; Lloyd, D.; Brown, N. A.; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005, 129, 528-536. (Pubitemid 41096641)
22. Chu, C.K.; Ma, T.; Shanmuganathan, K.; Wang, C.; Xiang, Y.; Pai, S. B.; Yao, G. Q.; Sommadossi, J. P.; Cheng, Y. C. Use of 2′-fluoro-5-methyl- beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 1995, 39, 979-981.
23. Balakrishna Pai, S.; Liu, S. H.; Zhu, Y. L.; Chu, C. K.; Cheng, Y. C. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluor-5- methyl-beta L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 1996, 40, 380-386.
24. Liu, S. H.; Grove, K. L.; Cheng, Y. C. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil: A substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob. Agents Chemother. 1998, 42, 833-839.
25. Yoo, B. C.; Kim, J. H.; Kim, T. H.; Koh, K. C.; Um, S. H.; Kim, Y. S.; Lee, K. S.; Han, B. H.; Chon, C. Y.; Han, J. Y.; Ryu, S. H.; Kim, H. C.; Byun, K. S.; Hwang, S. G.; Kim, B. I.; Cho, M.; Yoo, K.; Lee, H. J.; Hwang, J. S.; Kim, Y. S.; Lee, Y. S.; Choi, S. K.; Lee, Y. J.; Yang, J. M.; Park, J. W.; Lee, M. S.; Kim, D. G.; Chung, Y. H.; Cho, S. H.; Choi, J. Y.; Kweon, Y. O.; Lee, H. Y.; Jeong, S. H.; Yoo, H. W.; Lee, H. S. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007, 46, 1041-1048.
26. Yoo, B. C.; Kim, J. H.; Chung, Y. H.; Lee, K. S.; Paik, S. W.; Ryu, S. H.; Han, B. H.; Han, J. Y.; Byun, K. S.; Cho, M.; Lee, H. J.; Kim, T. H.; Cho, S. H.; Park, J. W.; Um, S. H.; Hwang, S. G.; Kim, Y. S.; Lee, Y. J.; Chon, C. Y.; Kim, B. I.; Lee, Y. S.; Yang, J. M.; Kim, H. C.; Hwang, J. S.; Choi, S. K.; Kweon, Y. O.; Jeong, S. H.; Lee, M. S.; Choi, J. Y.; Kim, D. G.; Kim, Y. S.; Lee, H. Y.; Yoo, K.; Yoo, H. W.; Lee, H. S. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007, 45, 1172-1178.
27. van Bommel, F.; Wunsche, T.; Mauss, S.; Reinke, P.; Bergk, A.; Schurmann, D.; Wiedenmann, B.; Berg, T. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004, 40, 1421-1425.
28. van Bommel, F.; Zollner, B.; Sarrazin, C.; Spengler, U.; Huppe, D.; Moller, B.; Feucht, H. H.; Wiedenmann, B.; Berg, T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006, 44, 318-325.
29. Delaney, W. E.; Ray, A. S.; Yang, H.; Qi, X.; Xiong, S.; Zhu, Y.; Miller, M. D. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 2006, 50, 2471-2477.
30. Marcellin, P.; Heathcote, E. J.; Buti, M.; Gane, E.; de Man, R. A.; Krastev, Z.; Germanidis, G.; Lee, S. S.; Flisiak, R.; Kaita, K.; Manns, M.; Kotzev, I.; Tchernev, K.; Buggisch, P.; Weilert, F.; Kurdas, O. O.; Shiffman, M. L.; Trinh, H.; Washington, M. K.; Sorbel, J.; Anderson, J.; Snow-Lampart, A.; Mondou, E.; Quinn, J.; Rousseau, F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 2008, 359, 2442-2455.
31. Fung, S. K.; Lok, A. S. Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B. Nat. Clin. Pract. Gastroenterol. Hepatol. 2004, 1, 90-97.
32. Fleischer, R. D.; Lok, A. S. Myopathy and neuropathy associated with nucleos (t) ide analog therapy for hepatitis B. J. Hepatol. 2009, 51, 787-791.
33. Rho, M.; Perazella, M. A. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr. Drug Saf. 2007, 2, 147-154.
34. Tanji, N.; Tanji, K.; Kambham, N.; Markowitz, G. S.; Bell, A.; D'agati, V. D. Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion. Hum. Pathol. 2001, 32, 734-740.
35. Kahn, J.; Lagakos, S.; Wulfsohn, M.; Cherng, D.; Miller, M.; Cherrington, J.; Hardy, D.; Beall, G.; Cooper, R.; Murphy, R.; Basgoz, N.; Ng, E.; Deeks, S.; Winslow, D.; Toole, J. J.; Coakley, D. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 1999, 282, 2305-2312.
36. Martin, J. L.; Brown, C. E.; Matthews-Davis, N.; Reardon, J. E. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 1994, 38, 2743-2749.
37. Kakuda, T. N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 2000, 22, 685-708.
38. Lewis, W.; Day, B. J.; Copeland, W. C. Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat. Rev. Drug. Discov. 2003, 2, 812-822.
39. Seok, J. I.; Lee, D. K.; Lee, C. H.; Park, M. S.; Kim, S. Y.; Kim, H. S.; Jo, H. Y.; Lee, C. H.; Kim, D. S. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49, 2080-2086.
40. Girones, R.; Miller, R. H. Mutation rate of the hepadnavirus genome. Virology 1989, 170, 595-597.
41. Nowak, M. A.; Bonhoeffer, S.; Hill, A. M.; Boehme, R.; Thomas, H. C.; McDade, H. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 1996, 93, 4398-4402.
42. Ngui, S. L.; Hallet, R.; Teo, C. G. Natural and iatrogenic variation in hepatitis B virus. Rev. Med. Virol. 1999, 9, 183-209.
43. Ghany, M.; Liang, T. J. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007, 132, 1574-1585.
44. Zoulim, F.; Locarnini, S. Hepatitis B virus resistance to nucleos (t) ide analogues. Gastroenterology 2009, 137, 1593-1608.
45. Lok, A. S.; Lai, C. L.; Leung, N.; Yao, G. B.; Cui, Z. Y.; Schiff, E. R.; Dienstag, J. L.; Heathcote, E. J.; Little, N. R.; Griffiths, D. A.; Gardner, S. D.; Castiglia, M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125, 1714-1722.
46. Allen, M. I.; Deslauriers, M.; Andrews, C. W.; Tipples, G. A.; Walters, K. A.; Tyrrell, D. L.; Brown, N.; Condreay, L. D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27, 1670-1677.
47. Stuyver, L. J.; Locarnini, S. A.; Lok, A.; Richman, D. D.; Carman, W. F.; Dienstag, J. L.; Schinazi, R. F. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001, 33, 751-757.
48. Warner, N.; Locarnini, S.; Kuiper, M.; Bartholomeusz, A.; Ayres, A.; Yuen, L.; Shaw, T. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob. Agents Chemother. 2007, 51, 2285-2292.
49. th.; Yang, H.; Westland, C. E.; Das, K.; Arnold, E.; Gibbs, C. S.; Miller, M. D.; Xiong, S. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 2003, 77, 11833-11841.
50. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
51. Das, K.; Xiong, X.; Yang, H.; Westland, C. E.; Gibbs, C. S.; Sarafianos, S. G.; Arnold, E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 2001, 75, 4771-4779.
52. Yang, H.; Westland, C. E.; Delaney, W. E.; Heathcote, E. J.; Ho, V.; Fry, J.; Brosgart, C.; Gibbs, C. S.; Miller, M. D.; Xiong, S. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36, 464-473.
53. Hadziyannis, S. J.; Tassopoulos, N. C.; Heathcote, E. J.; Chang, T. T.; Kitis, G.; Rizzetto, M.; Marcellin, P.; Lim, S. G.; Goodman, Z.; Ma, J.; Brosgart, C. L.; Borroto-Esoda, K.; Arterburn, S.; Chuck, S. L. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131, 1743-1751. (Pubitemid 44958517)
54. Angus, P.; Vaughan, R.; Xiong, S.; Yang, H.; Delaney, W.; Gibbs, C.; Brosgart, C.; Colledge, D.; Edwards, R.; Ayres, A.; Bartholomeusz, A.; Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125, 292-297.
55. Brunelle, M. N.; Jacquard, A. C.; Pichoud, C.; Durantel, D.; Carrouee-Durantel, S.; Villeneuve, J. P.; Trepo, C.; Zoulim F. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005, 41, 1391-1398.
56. Villet, S.; Pichoud, C.; Billioud, G.; Barraud, L.; Durantel, S.; Trépo, C.; Zoulim, F. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008, 48, 747-755.
57. Colonno, R. J.; Rose, R.; Baldick, C. J.; Levine, S.; Pokornowski, K.; Yu, C. F.; Walsh, A.; Fang, J.; Hsu, M.; Mazzucco, C.; Eggers, B.; Zhang, S.; Plym, M.; Klesczewski, K.; Tenney, D. J. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44, 1656-1665.
58. Tenney, D. J.; Rose, R. E.; Baldick, C. J.; Pokornowski, K. A.; Eggers, B. J.; Fang, J.; Wichroski, M. J.; Xu, D.; Yang, J.; Wilber, R. B.; Colonno, R. J. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 2009, 49, 1503-1514.
59. Tenney, D. J.; Levine, S. M.; Rose, R. E.; Walsh, A. W.; Weinheimer, S. P.; Discotto, L.; Plym, M.; Pokornowski, K.; Yu, C. F.; Angus, P.; Ayres, A.; Bartholomeusz, A.; Sievert, W.; Thompson, G.; Warner, N.; Locarnini, S.; Colonno, R. J. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 2004, 48, 3498-3507.
60. Nash, K. Telbivudine in the treatment of chronic hepatitis B. Adv. Ther. 2009, 26, 155-169.
61. Locarnini, S.; Mason, W. S. Cellular and virological mechanisms of HBV drug resistance. J. Hepatol. 2006, 44, 422-431.
62. Seifer, M.; Patty, A.; Serra, I.; Li, B.; Standring, D. N. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009, 81, 147-155.
63. Yamamoto, T.; Litwin, S.; Zhou, T.; Zhu, Y.; Condreay, L.; Furman, P.; Mason, W. S. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil. J. Virol. 2002, 76, 1213-1223.
64. Ono, S. K.; Kato, N.; Shiratori, Y.; Kato, J.; Goto, T.; Schinazi, R. F.; Carrilho, F. J.; Omata, M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Invest. 2001, 107, 449-455.
65. Chin, R.; Shaw, T.; Torresi, J.; Sozzi, V.; Trautwein, C.; Bock, T.; Manns, M.; Isom, H.; Furman, P.; Locarnini, S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2, 6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 2001, 45, 2495-2501.
66. Sheldon, J.; Camino, N.; Rodés, B.; Bartholomeusz, A.; Kuiper, M.; Tacke, F.; Núñez, M.; Mauss, S.; Lutz, T.; Klausen, G.; Locarnini, S.; Soriano, V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther. 2005, 10, 727-734.
67. Amini-Bavil-Olyaee, S.; Herbers, U.; Sheldon, J.; Luedde, T.; Trautwein, C.; Tacke, F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009, 49, 1158-1165.
68. Langley, D. R.; Walsh, A. W.; Baldick, C. J.; Eggers, B. J.; Rose, R. E.; Levine, S. M.; Kapur, A. J.; Colonno, R. J.; Tenney, D. J. Inhibition of hepatitis B virus polymerase by entecavir. J. Virol. 2007, 81, 3992-4001.
69. Lin, X.; Yuan, Z. H.; Wu, L.; Ding, J. P.; Wen, Y. M. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J. Virol. 2001, 75, 11827-11833.
70. Sharon, A.; Chu, C. K. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res. 2008, 80, 339-353.
71. Bartholomeusz, A.; Tehan, B. G.; Chalmers, D. K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 2004, 9, 149-160.
72. Daga, P. R.; Duan, J.; Doerksen, R. J. Computational model of hepatitis B virus DNA polymerase: Molecular dynamics and docking to understand resistant mutations. Protein Sci. 2010, 19, 796-807.
73. Xiong, X.; Flores, C.; Yang, H.; Toole, J. J.; Gibbs, C. S. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998, 28, 1669-1673.
74. Aloman, C.; Wands, J. R. Resistance of HBV to adefovir dipivoxil: A case for combination antiviral therapy? Hepatology 2003, 38, 1584-1587.
75. Dando, T.; Plosker, G. Adefovir dipivoxil: A review of its use in chronic hepatitis B. Drugs 2003, 63, 2215-2234.
76. Yadav, V.; Chu, C. K. Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: A molecular dynamics study. Bioorg. Med. Chem. Lett. 2004, 14, 4313-4317.
77. Michalak, T. I.; Zhang, H.; Churchill, N. D.; Larsson, T.; Johansson, N. G.; Oberg, B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob. Agents Chemother. 2009, 53, 3803-3814.
78. Zhu, Y. L.; Dutschman, D. E.; Liu, S. H.; Bridges, E. G.; Cheng, Y. C. Anti-hepatitis B virus activity and metabolism of 2′, 3′-dideoxy- 2′, 3′-didehydro-beta-L (-)-5-fluorocytidine. Antimicrob. Agents Chemother. 1998, 42, 1805-1810.
79. Choi, J. R.; Cho, D. G.; Roh, K. Y.; Hwang, J. T.; Ahn, S.; Jang, H. S.; Cho, W. Y.; Kim, K. W.; Cho, Y. G.; Kim, J.; Kim, Y. Z. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)-methyl]guanine as a potent and selective anti-HBV agent. J. Med. Chem. 2004, 47, 2864-2869.
80. Fung, J.; Lai, C. L.; Yuen, M. F. LB80380: A promising new drug for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs. 2008, 17, 1581-1588.
81. Yuen, M. F.; Lee, S. H.; Kang, H. M.; Kim, C. R.; Kim, J.; Ngai, V.; Lai, C. L. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob. Agents Chemother. 2009, 53, 1779-1785.
82. Yuen, M. F.; Han, K. H.; Um, S. H.; Yoon, S. K.; Kim, H. R.; Kim, J.; Kim, C. R.; Lai, C. L. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010, 51, 767-776.
83. Reddy, K. R.; Matelich, M. C.; Ugarkar, B. G.; Gómez-Galeno, J. E.; DaRe, J.; Ollis, K.; Sun, Z.; Craigo, W.; Colby, T. J.; Fujitaki, J. M.; Boyer, S. H.; van Poelje, P. D.; Erion, M. D. Pradefovir: A prodrug that targets adefovir to the liver for the treatment of hepatitis B. J. Med. Chem. 2008, 14, 666-676.
84. Lim, S. G.; Lai, C. L.; Myers, M. Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B (abstract). J. Hepatol. 2005, 42(Suppl 2), 16.
85. Zhang, Q.; Jiang, Z. Y.; Luo, J.; Cheng, P.; Ma, Y. B.; Zhang, X. M.; Zhang, F. X.; Zhou, J.; Chen, J. J. Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: A new class of hepatitis B virus inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 4647-4650.
86. Zhang, Q.; Jiang, Z. Y.; Luo, J.; Liu, J. F.; Ma, Y. B.; Guo, R. H.; Zhang, X. M.; Zhou, J.; Chen, J. J. Anti-HBV agents. Part 2: Synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives. Bioorg. Med. Chem. Lett. 2009, 19, 2148-2153.
87. Zhang, Q.; Jiang, Z. Y.; Luo, J.; Ma, Y. B.; Liu, J. F.; Guo, R. H.; Zhang, X. M.; Zhou, J.; Niu, W.; Du, F. F.; Li, L.; Li, C.; Chen, J. J. Anti-HBV agents. Part 3: Preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors. Bioorg. Med. Chem. Lett. 2009, 19, 6659-6665.
88. Shin, M. S.; Kang, E. H.; Lee, Y. I. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. Antiviral Res. 2005, 67, 163-168.
89. Dougherty, A. M.; Guo, H.; Westby, G.; Liu, Y.; Simsek, E.; Guo, J. T.; Mehta, A.; Norton, P.; Gu, B.; Block, T.; Cuconati, A. A substituted tetrahydro-tetrazolo-pyrimidine is a specific and novel inhibitor of hepatitis B virus surface antigen secretion. Antimicrob. Agents Chemother. 2007, 51, 4427-4437.
90. Su, C. R.; Yeh, S. F.; Liu, C. M.; Damu, A. G.; Kuo, T. H.; Chiang, P. C.; Bastow, K. F.; Lee, K. H.; Wu, T. S. Anti-HBV and cytotoxic activities of pyranocoumarin derivatives. Bioorg. Med. Chem. 2009, 17, 6137-6143.
91. Asif-Ullah, M.; Choi, K. J.; Choi, K. I.; Jeong, Y. J.; Yu, Y. G. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. Antiviral Res. 2006, 70, 85-90.
92. Deres, K.; Schröder, C. H.; Paessens, A.; Goldmann, S.; Hacker, H. J.; Weber, O.; Krämer, T.; Niewöhner, U.; Pleiss, U.; Stoltefuss, J.; Graef, E.; Koletzki, D.; Masantschek, R. N.; Reimann, A.; Jaeger, R.; Gross, R.; Beckermann, B.; Schlemmer, K. H.; Haebich, D.; Rübsamen-Waigmann, H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003, 299, 893-896.
93. th.; Edwards, R.; Colledge, D.; Shaw, T.; Furman, P.; Painter, G.; Locarnini, S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 2002, 46, 3057-3560.
94. King, R. W.; Ladner, S. K.; Miller, T. J.; Zaifert, K.; Perni, R. B.; Conway, S. C.; Otto, M. J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-) beta-L-2′, 3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 1998, 42, 3179-31486.
95. Feld, J. J.; Colledge, D.; Sozzi, V.; Edwards, R.; Littlejohn, M.; Locarnini, S. A. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res. 2007, 76, 168-177.
96. Liu, Y.; Zhao, Y.; Zhai, X.; Feng, X.; Wang, J.; Gong, P. Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3- carboxylates in vitro. Bioorg. Med. Chem. 2008, 16, 6522-6527.
97. Li, Y.; Fu, L.; Yeo, H.; Zhu, J. L.; Chou, C. K.; Kou, Y. H.; Yeh, S. F.; Gullen, E.; Austin, D.; Cheng, Y. C. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative. Antivir. Chem. Chemother. 2005, 16, 193-201. (Pubitemid 41512160)
98. Ying, C.; Li, Y.; Leung, C. H.; Robek, M. D.; Cheng, Y. C. Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue. Proc. Natl. Acad. Sci. USA 2007, 104, 8526-8531.
99. Li, Y. F.; Wang, G. F.; He, P. L.; Huang, W. G.; Zhu, F. H.; Gao, H. Y.; Tang, W.; Luo, Y.; Feng, C. L.; Shi, L. P.; Ren, Y. D.; Lu, W.; Zuo, J. P. Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives. J. Med. Chem. 2006, 49, 4790-4794.
100. Li, Y. F.; Wang, G. F.; Luo, Y.; Huang, W. G.; Tang, W.; Feng, C. L.; Shi, L. P.; Ren, Y. D.; Zuo, J. P.; Lu, W. Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus. Eur. J. Med. Chem. 2007, 42, 1358-1364.
101. Lv, Z.; Sheng, C.; Wang, T.; Zhang, Y.; Liu, J.; Feng, J.; Sun, H.; Zhong, H.; Niu, C.; Li, K. Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives. J. Med. Chem. 2010, 53, 660-668.
102. Zembower, D. E.; Lin, Y. M.; Flavin, M. T.; Chen, F. C.; Korba, B. E. Robustaflavone, a potential non-nucleoside anti-hepatitis B agent. Antiviral Res. 1998, 39, 81-88.
103. Dong, W. L.; Liu, Z. X.; Liu, X. H.; Li, Z. M.; Zhao, W. G. Synthesis and antiviral activity of new acrylamide derivatives containing 1, 2, 3-thiadiazole as inhibitors of hepatitis B virus replication. Eur. J. Med. Chem. 2010, 45, 1919-1926.
104. Xu, B.; Huang, Z.; Liu, C.; Cai, Z.; Pan, W.; Cao, P.; Hao, X.; Liang, G. Synthesis and antihepatitis B virus activities of Matijing-Su derivatives. Bioorg. Med. Chem. 2009, 17, 3118-3125.
105. Korba, B. E.; Montero, A. B.; Farrar, K.; Gaye, K.; Mukerjee, S.; Ayers, M. S. Rossignol, J. F. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res. 2008, 77, 56-63.
106. Zhao, C.; Zhao, Y.; Chai, H.; Gong, P. Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3- carboxylates. Bioorg. Med. Chem. 2006, 14, 2552-2558. (Pubitemid 43343642)
107. Guo, Q.; Zhao, L.; You, Q.; Yang, Y.; Gu, H.; Song, G.; Lu, N.; Xin, J. Anti-hepatitis B virus activity of wogonin in vitro and in vivo. Antiviral Res. 2007, 74, 16-24.
108. Romero, M. R.; Efferth, T.; Serrano, M. A.; Castaño, B.; Macias, R. I.; Briz, O.; Marin, J. J. Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res. 2005, 68, 75-83.
109. Zhang, P.; Zhang, N.; Korba, B. E.; Hosmane, R. S. Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4, 5-e][1, 3]diazepine-4, 8-dione ring system. Bioorg. Med. Chem. Lett. 2005, 15, 5397-5401.
110. Lee, J.; Shim, H.; Park, Y.; Park, S.; Shin, J.; Yang, W.; Lee, H.; Park, W.; Chung, Y.; Lee, S. 2, 5-Pyridinedicarboxylic acid derivatives as non-nucleosidic reverse transcriptase inhibitors of hepatitis B virus. Bioorg. Med. Chem. Lett. 2002, 12, 2715-2717.
111. Zhu, Y. L.; Pai, S. B.; Liu, S. H.; Grove, K. L.; Jones, B. C.; Simons, C.; Zemlicka, J.; Cheng, Y. C. Inhibition of replication of hepatitis B virus by cytallene in vitro. Antimicrob. Agents Chemother. 1997, 41, 1755-1760.
112. Kim, K. H.; Kim, N. D.; Seong, B. L. Pharmacophore-based virtual screening: A review of recent applications. Expert Opin. Drug Discov. 2010, 5, 205-222.
113. Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors. J. Chem. Inf. Model. 2010, 50, 662-676.
114. Ryu, K.; Kim, N. D.; Choi, S. I.; Han, C. K.; Yoon, J. H.; No, K. T.; Kim, K. H.; Seong, B. L. Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophorebased virtual screening and in vitro evaluation. Bioorg. Med. Chem. 2009, 17, 2975-2982.
115. Kim, J.; Kim, K. S.; Kim, D. E.; Chong, Y. Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening. Chem. Biol. Drug. Des. 2008, 72, 585-591.
116. Bustanji, Y.; Al-Masri, I. M.; Qasem, A.; Al-Bakri, A. G.; Taha, M. O. In silico screening for nonnucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and highthroughput docking followed by in vitro evaluation. Chem. Biol. Drug. Des. 2009, 74, 258-265.
117. De Luca, L.; Barreca, M. L.; Ferro, S.; Christ, F.; Iraci, N.; Gitto, R.; Monforte, A. M.; Debyser, Z.; Chimirri, A. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. Chem Med Chem 2009, 4, 1311-1316.
118. Carrieri, A.; Pérez-Nueno, V. I.; Fano, A.; Pistone, C.; Ritchie, D. W.; Teixidó, J. Biological profiling of anti-HIV agents and insight into CCR5 antagonist binding using in silico techniques. Chem Med Chem 2009, 4, 1153-1163.
119. Jones, G.; Willett, P.; Glen, R. C. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput. Aided. Mol. Des. 1995, 9, 532-549.
120. Walsh, A. W.; Langley, D. R.; Colonno, R. J.; Tenney, D. J. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One. 2010, 5, e9195.
121. Belloni, L.; Pollicino, T.; De Nicola, F.; Guerrieri, F.; Raffa, G.; Fanciulli, M.; Raimondo, G.; Levrero, M. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl. Acad. Sci. USA 2009, 106, 19975-19979.
122. Levrero, M.; Pollicino, T.; Petersen, J.; Belloni, L.; Raimondo, G.; Dandri, M. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 2009, 51, 581-592.
123. Guo, Y.; Li, Y.; Mu, S.; Zhang, J.; Yan, Z. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. J. Med. Virol. 2009, 81, 1177-1183.
124. Pollicino, T.; Belloni, L.; Raffa, G.; Pediconi, N.; Squadrito, G.; Raimondo, G.; Levrero, M. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006, 130, 823-837.
125. Petersen, J.; Dandri, M.; Mier, W.; Lütgehetmann, M.; Volz, T.; von Weizsäcker, F.; Haberkorn, U.; Fischer, L.; Pollok, J. M.; Erbes, B.; Seitz, S.; Urban, S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat. Biotechnol. 2008, 26, 335-341.
126. McCaffrey, A. P.; Nakai, H.; Pandey, K.; Huang, Z.; Salazar, F. H.; Xu, H.; Wieland, S. F.; Marion, P. L.; Kay, M. A. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 2003, 21, 639-644.
127. Morrissey, D. V.; Lockridge, J. A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C. S.; Jeffs, L. B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 2005, 23, 1002-1007.
128. Wu, H. L.; Huang, L. R.; Huang, C. C.; Lai, H. L.; Liu, C. J.; Huang, Y. T.; Hsu, Y. W.; Lu, C. Y.; Chen, D. S.; Chen, P. J. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005, 128, 708-716.
129. Bouchard, M. J.; Wang, L. H.; Schneider, R. J. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001, 294, 2376-2378.
130. Schulze, A.; Gripon, P.; Urban, S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 2007, 46, 1759-1768.
131. Lee, Y. S.; Kennedy, W. D.; Yin, Y. W. Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell 2009, 139, 312-324.
132. Erratum in: Cell 2009, 139, 828.
133. Falkenberg, M.; Larsson, N. G. Structure casts light on mtDNA replication. Cell 2009, 139, 231-233.